Avatar

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequencing

By Morie Gertz 6 Videos
March 25, 2020
3 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
The O'Neal Comprehensive Cancer Center at UAB

UAB Hematology Review 2021

Fri, Mar 5, 2021
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
14:16
2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do Tri…

Feat. K. Anderson
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achi…

Feat. T. Martin
15:22
SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…

Feat. M. Claudio Da Via
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Myelo…

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…

Feat. S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

08:25
Cristina Gasparetto

2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...

15:52
Thomas Martin

ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consider Is…

27:01
SOHO Italy 1st School of Multiple Myeloma

Europe vs. USA Experience in MM: Access to New Drugs (Off-Label vs Approve…

Feat. K. Anderson